Solstice, a full-service, woman-owned, communications agency is excited to announce that its patient journey project has been documented and published in the May issue of the Orphanet Journal of Rare Diseases, the portal for rare diseases and orphan drugs. “Mapping the PIK3CA-Related Overgrowth Spectrum (PROS) Patient and Caregiver Journey Using a Patient-Centered Approach” explains how Solstice used its novel methodology to develop a patient engagement roadmap for PROS conditions. The article can be accessed online via PubMed (Orphanet J Rare Dis 2022 May 7;17(1):189. doi: 10.1186/s13023-022-02338-1.)
A large pharmaceutical company selected Solstice to develop this journey, which was created in concert with patients, caregivers, and advocates as key partners. The interactive visualization of the PROS journey identifies areas of unmet need, barriers to care, and education topics, and has been used as a core strategic planning tool for disease awareness and launch readiness. “This type of work, spearheaded by one of our Certified Health Education Specialists, is essential for pharmaceutical companies looking to understand the patient experience and areas of unmet need, particularly in the rare disease space,” according to Nanske Wood, President of Solstice.
Patient engagement is increasingly recognized as an integral part of patient-centered healthcare. A better understanding of the entire patient experience through this journey analysis method will help Pharma/Biotech develop the appropriate patient and caregiver strategies to effectively address educational and support needs.
To find out more regarding how this unique methodology could benefit your brand/marketing efforts, contact Nanske Wood at nwood@solsticehc.net or 973-879-3819.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.